B
BioMarin Pharmaceutical Inc.
BMRN · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
The Market Forgot That Rare Disease Franchises Compound Quietly
Most investors look at Roctavian's failure and discount the entire platform — but that misreads the situation entirely. The ERT annuities never needed gene therapy to be excellent businesses, Voxzogo's international patient identification is barely underway, and the stock trades as if the competitive threat from TransCon CNP is a certainty rather than a risk being actively managed by a company that already has a second-generation answer in clinical development.
Flowly Score
Apr 16 Close
+113%$54.10
Fair Value
$115.00
68
Strongat $54.10
Business Strength7/10
The ERT franchise is a genuine medical subscription business with biological moats that don't expire when patents do — switching costs are enforced by clinical reality, not contracts. The blemish is a capital allocation track record that demonstrates a culture historically better at making drugs than making economic decisions, now mid-correction under new leadership.
Financial Resilience7/10
The FCF inflection is real — a business that ran near break-even on free cash for years is now generating mid-twenties FCF margins, and the cash pile dwarfs the debt load. The forward risk is that the Amicus acquisition adds integration complexity and capital consumption precisely when the business had finally cleared the infrastructure build-out phase.
Growth & Trajectory7/10
Voxzogo's international underpenetration is the clearest near-term runway — achondroplasia awareness outside the US is still low enough that the addressable patient pool hasn't been seriously touched, and the infant cohort strategy creates a protected competitive window. The trajectory depends heavily on whether BMN 333 arrives as a genuine upgrade before TransCon CNP changes the competitive landscape.
Valuation7/10at $58.51
A rare disease platform generating substantial free cash flow, trading at a mid-teens multiple on that cash flow, with a pessimistic DCF that still implies meaningful upside — the market appears to be discounting for competitive risk that is real but already visible and partially manageable. The gap between price and fair value is wide enough to be interesting without being cheap enough to be obvious.
Risk5/10
The risk stack is unusually specific: a direct competitive attack on the primary growth engine from a well-capitalized rival, European HTA bodies increasingly treating orphan drugs like commodities, and a pending acquisition that adds integration risk to an organization still rebuilding its capital allocation credibility. None are existential, but they stack in ways that could erode the thesis simultaneously.
BioMarin sits at an unusual intersection: a genuinely durable franchise with sticky recurring revenues, trading at a multiple that implies the market has written off its growth prospects almost entirely. The FCF yield alone tells you something is mispriced — a business compounding revenue at double digits and generating accelerating free cash flow doesn't normally trade at these multiples unless the market believes the good times are ending. The quality of the underlying ERT franchise is underappreciated; these are biological medicines administered indefinitely to patients with no alternatives, and the competitive dynamics for a physician treating a child with MPS IV simply aren't comparable to any commodity drug market. The business is moving in the right direction on almost every axis that matters for a five-year hold. The infrastructure build-out is complete, the commercial organization is learning discipline, Voxzogo's international expansion is a multi-year runway, and the pipeline — particularly BMN 351's dystrophin data, which is early but genuinely striking — suggests the next platform catalyst is already in motion. Management's focus on infant achondroplasia patients creates something competitors will struggle to replicate quickly: years of safety and titration data in the youngest and most important cohort, the kind of clinical evidence that moves reimbursement bodies and gives physicians confidence. The single biggest risk, named precisely, is Ascendis TransCon CNP. If a long-acting competitor earns physician confidence through convenience and comparable safety, Voxzogo faces volume erosion and pricing pressure at exactly the moment its revenues are funding Amicus integration, BMN 333 development, and the rest of the pipeline. The bull case requires that BMN 333's Phase II/III data reads out cleanly and quickly enough to reassert best-in-class status before market share shifts become structural — a binary outcome that management has correctly identified as the strategic priority, but which still carries all the uncertainty of a pivotal clinical trial.